Eric Angevin

12.9k citations

140 papers · 6.5k indexed · 2 hit papers · h-index 38

Impact in

Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
Cancer Research top 0.5%
- MicroRNA in disease regulation

Papers in ⓘ

Oncology 70
- Cancer Immunotherapy and Biomarkers 40
- CAR-T cell therapy research 16
- HER2/EGFR in Cancer Research 12
Immunology 47
- Immunotherapy and Immune Responses 34
- Immune Cell Function and Interaction 18
- T-cell and B-cell Immunology 15

Co-authors: Laurence Zitvogel (22 shared papers)Thomas Tursz (10 shared papers)Caroline Flament (12 shared papers)Sebastián Amigorena (5 shared papers)Graça Raposo (5 shared papers)Bernard Escudier (29 shared papers)Fabrice André (11 shared papers)Joseph Wolfers (3 shared papers)
Journals: Annals of Oncology (23 papers)Journal of Clinical Oncology (23 papers)International Journal of Cancer (10 papers)European Journal of Cancer (9 papers)Clinical Cancer Research (6 papers)
Partner nations: France United States Netherlands

In The Last Decade

Eric Angevin

134 papers receiving 6.4k citations

Hit Papers

align trajectories log scale

Malignant effusions and immunogenic tumour-derived exosomes 2002 · 793 citations

Peers

Countries citing papers authored by Eric Angevin

Since Specialization

Citations

This map shows the geographic impact of Eric Angevin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Angevin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Angevin more than expected).

Fields of papers citing papers by Eric Angevin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Angevin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Angevin. The network helps show where Eric Angevin may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Angevin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Angevin Line = papers co-authored together Eric Angevin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 140 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming Nature Medicine ·Joseph Wolfers, Anne Lozier, Graça Raposo, Armelle Régnault, Clotilde Théry, Carole Masurier, Caroline Flament, Stéphanie Pouzieux, Florence Faure, Thomas Tursz, Eric Angevin, Sebastián Amigorena, Laurence Zitvogel Hit paper breakdown →	2001	1347
2	Malignant effusions and immunogenic tumour-derived exosomes The Lancet ·Fabrice André, Noël E.C. Schartz, Mojgan Movassagh, Caroline Flament, Patricia Pautier, Philippe Morice, Christophe Pomel, Catherine Lhommé, Bernard Escudier, Thierry Le Chevalier, Thomas Tursz, Sebastián Amigorena, Graça Raposo, Eric Angevin, Laurence Zitvogel Hit paper breakdown →	2002	793
3	Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells The Journal of Immunology ·Fabrice André, Nathalie Chaput, Noël E.C. Schartz, Caroline Flament, N. Aubert, Jacky Bernard, François A. Lemonnier, Graça Raposo, Bernard Escudier, Di‐Hwei Hsu, Thomas Tursz, Sebastián Amigorena, Eric Angevin, Laurence Zitvogel	2004	418
4	Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection The Journal of Immunology ·Nathalie Chaput, Noël E.C. Schartz, Fabrice André, Julien Taı̈eb, Sophie Novault, Pierre Bonnaventure, N. Aubert, Jacky Bernard, François A. Lemonnier, Miriam Mérad, Gosse J. Adema, Malcolm Adams, Maria Ferrantini, Alain Carpentier, Bernard Escudier, Thomas Tursz, Eric Angevin, Laurence Zitvogel	2004	224
5	Tumor-derived exosomes: a new source of tumor rejection antigens Vaccine ·Fabrice André, N. Schartz, Nathalie Chaput, Caroline Flament, Graça Raposo, Sebastián Amigorena, Eric Angevin, Laurence Zitvogel	2002	176
6	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) European Journal of Cancer ·Frédéric Bigot, Eduardo Castañón, Capucine Baldini, Antoine Hollebecque, Alberto Carmona‐Bayonas, Sophie Postel‐Vinay, Eric Angevin, Jean‐Pierre Armand, Vincent Ribrag, Sandrine Aspeslagh, Andréa Varga, Rastislav Bahleda, Jessica Menis, Anas Gazzah, Jean‐Marie Michot, Aurélien Marabelle, Jean‐Charles Soria, Christophe Massard	2017	145
7	Exosomes as a Tumor Vaccine: Enhancing Potency Through Direct Loading of Antigenic Peptides Journal of Immunotherapy ·Di‐Hwei Hsu, Pedro Paz, Gilbert Villaflor, Alberto Rivas, Anita Mehta‐Damani, Eric Angevin, Laurence Zitvogel, Jean‐Bernard Le Pecq	2003	138
8	Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. PubMed ·El Chérif Ibrahim, Nadia Guerra, M. J. Lacombe, Eric Angevin, Salem Chouaı̈b, Edgardo D. Carosella, Anne Caignard, Pascale Paul	2001	136
9	Exosome-based immunotherapy Cancer Immunology Immunotherapy ·Nathalie Chaput, Julien Ta�eb, N. Schartz, Fabrice Andr�, Eric Angevin, Laurence Zitvogel	2004	113
10	Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation ·Pascal Merlet, J. Delforge, A. Syrota, Eric Angevin, B. Mazièré, C. Crouzel, Héric Valette, D Loisance, A Castaigne, Jean Luc Dubois Randé	1993	112
11	Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma Clinical Cancer Research ·Bernard Escudier, Nathalie Lassau, Eric Angevin, Jean Charles Soria, L. Chami, Michele Lamuraglia, Eric Zafarana, Veronique Landreau, Brian Schwartz, Eric Brendel, Jean‐Pierre Armand, Caroline Robert	2007	109
12	Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation Clinical Cancer Research ·Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andréa Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah, Jean‐Marie Michot, Sophie Postel‐Vinay, Eric Angevin, Vincent Ribrag, Antoine Hollebecque, Jean‐Charles Soria, Caroline Robert, Christophe Massard, Aurélien Marabelle	2018	106
13	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwani, Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, Karen Kelly	2018	104
14	Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma Clinical Cancer Research ·Eric Angevin, José A. López-Martín, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Daniel Castellano, Jean‐Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, Bernard Escudier	2013	103
15	T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. The Journal of Immunology ·Françoise Farace, Florence Orlanducci, Pierre‐Yves Dietrich, Catherine Gaudin, Eric Angevin, Marie Hélène Courtier, C Bayle, Thierry Hercend, Frédéric Triebel	1994	95
16	Exosomes for cancer immunotherapy Annals of Oncology ·Fabrice André, Bernard Escudier, Eric Angevin, Thomas Tursz, Laurence Zitvogel	2004	87
17	Phase II trial of thalidomide in renal-cell carcinoma Annals of Oncology ·Bernard Escudier, Nathalie Lassau, D. Couanet, Eric Angevin, Francine Mesrati, S. Leborgne, A. Garofano, Christophe Leboulaire, N. Dupouy, A. Laplanche	2002	86
18	Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma Cancer Research ·Mojgan Movassagh, Alan Spatz, Jean Davoust, Serge Lebecque, Pedro Romero, Mikäel J. Pittet, Donata Rimoldi, D Liénard, O. Gugerli, Laurent Ferradini, Caroline Robert, Marie‐Françoise Avril, Laurence Zitvogel, Eric Angevin	2004	85
19	A hsp70-2 Mutation Recognized by CTL on a Human Renal Cell Carcinoma The Journal of Immunology ·Catherine Gaudin, Florence Kremer, Eric Angevin, Véronique Scott, Frédéric Triebel	1999	80
20	Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Alexander I. Spira, Eric Angevin, Wu‐Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly	2022	68

About Eric Angevin

Eric Angevin is a scholar working on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 140 papers that have together received 6.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (40 papers), Immunotherapy and Immune Responses (34 papers), Lung Cancer Treatments and Mutations (21 papers), Immune Cell Function and Interaction (18 papers), CAR-T cell therapy research (16 papers), T-cell and B-cell Immunology (15 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and HER2/EGFR in Cancer Research (12 papers). The work is most often cited by research in Immunology (2.8k citations), Cancer Research (1.7k citations), Oncology (1.7k citations), Molecular Biology (3.8k citations) and Pulmonary and Respiratory Medicine (814 citations). Eric Angevin has collaborated with scholars based in France, United States and Netherlands. Frequent co-authors include Laurence Zitvogel, Thomas Tursz, Caroline Flament, Sebastián Amigorena, Graça Raposo, Bernard Escudier, Fabrice André, Joseph Wolfers, Anne Lozier and Clotilde Théry. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, International Journal of Cancer, European Journal of Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact